Abstracts tagged "COVID-19"

Abstract Number: 1093 • ACR Convergence 2023
Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Liam Huppke¹, Paul Wratil², Marie Bischof², Stefan Wolfrum¹, Fabian Ullrich¹, Delila Singh¹, Julia Lichtnekert¹, Lea Grümme¹, Christina Gebhardt¹, Klaus Krüger³, Franziska Wiesent⁴, Alla Skapenko¹, Oliver Keppler⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ²Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius, Munich, Germany, ⁴Endokrinologikum München, Munich, Germany, ⁵Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, ⁶Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany
Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…
Abstract Number: 1677 • ACR Convergence 2023
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Abhishek Abhishek¹, Nicholas Peckham², Corinna Pade³, Joseph Gibbons³, Lucy Cureton², Anne Francis², Vicki Barber², Jennifer Williams², duncan Appelbe², lucy Eldridge², patrick Julier², daniel Altmann⁴, James Bluett⁵, Tim Brooks⁶, Laura Coates², ines Rombach⁷, Amanda Semper⁶, Ashley Otter⁶, Ana Valdes¹, Jonathan Nguyen-Van-Tam¹, Hywel Williams¹, Aine McKnight³, Rosemary Boyton⁴ and jonathan Cook², ¹University of Nottingham, Nottingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴Imperial College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶UK Health Security Agency, Porton Down, United Kingdom, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Emily Kowalski¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade³, Shruthi Srivatsan², Zachary Williams², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…
Abstract Number: 1141 • ACR Convergence 2023
COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience
Vincent Luceño¹, Peter Paolo Daleon¹ and Sandra Navarra², ¹University of Santo Tomas Hospital, City of Manila, Philippines, ²University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
Abstract Number: 1754 • ACR Convergence 2023
Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19
Maya Amjadi¹, Maxwell Parker², Zihao Zheng¹, Alex Robbins¹, Michael Denny¹, Sara McCoy³, Irene Ong¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Middleton, WI
Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
Abstract Number: 2036 • ACR Convergence 2023
Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters
Todd Wilson¹, Paul R. Fortin², Ines Colmegna³, Sonia Theriault⁴, Nathalie Amiable⁵, Alexandra Godbout⁵ and Glen Hazlewood¹, ¹University of Calgary, Calgary, AB, Canada, ²Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada
Background/Purpose: COVID-19 vaccines are now being offered as regular boosters every 6-12 months for people with autoimmune rheumatic diseases, particularly for people on rituximab, where…
Abstract Number: 2564 • ACR Convergence 2023
The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial
Jennifer Hanberg¹, Xiaoqing Fu¹, Xiaosong Wang², Naomi Patel¹, Yumeko Kawano², Abigail Schiff², Emily Kowalski², Claire Cook¹, Kathleen Vanni², Krishan Guzzo¹, Grace Qian², Katarina Bade³, Alene Saavedra², Rathnam Venkat², Shruthi Srivatsan¹, Yuqing Zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace⁶, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Many patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulators have blunted humoral responses to COVID-19 vaccines. As such, the initial mRNA vaccine series…
Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Hilde Ørbo¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Ingrid Christensen¹, Joseph Sexton¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Gunnveig Grødeland⁴, Ludvig A. Munthe⁵, Siri Mjaaland⁶, John Torgils Vaage⁵, Espen Haavardsholm¹, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
Abstract Number: 0225 • ACR Convergence 2023
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Yi-Ming Chen¹, Jun-Pen Chen², Chi-Wei Tseng², CARLOS ENRIQUE TORO GUTIERREZ³, Elena Nikiphorou⁴, Ai Lyn Tan⁵, Arvind Nune⁶, Esha Kadam⁷, Masataka Kuwana⁸, Jessica Day⁹, Sreoshy Saha¹⁰, Tsvetelina Velikova¹¹, James Lilleker¹², CARLO VINICIO CABALLERO¹³, Parikshit Sen¹⁴, Hector Chinoy¹⁵, Rohit Aggarwal¹⁶, Vikas Agarwal¹⁷ and Latika Gupta¹⁸, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan, ³Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ⁴King's College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ⁷Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Walter and Eliza Hall Institute, Melbourne, Australia, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹³REUMACARIBE IPS, Barranquilla, Colombia, ¹⁴Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁵The University of Manchester, Sale, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Existing studies have shown that disease activity of patients with rheumatoid arthritis (RA) may surge after COVID-19 infection. However, factors associated with disease flares…
Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Maximiliano Diaz Menindez¹, Megan Sullivan², Benjamin Wang³, Andy Abril³, Vikas Majithia², Ronald Butendieck³, Colleen T. Ball⁴ and Florentina Berianu², ¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Jacksonville, Jacksonville, FL
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Adam Titi¹, Ryan Adyniec², Nat Murren¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Minerva Nong¹, Medha Barbhaiya², Jonah Levine³, Vivian Bykerk⁴, Rachel Heise⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].